Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection

New England Journal of Medicine

Volumn 336, Issue 19, 1997, Pages 1343-1349

  Luzuriaga, Katherine ^a   Bryson, Yvonne ^b   Krogstad, Paul ^b   Robinson, James ^c   Stechenberg, Barbara ^d   Lamson, Michael ^e   Cort, Susannah ^e   Sullivan, John L ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^d BAYSTATE MEDICAL CENTER   (United States)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; IMMUNOGLOBULIN G ANTIBODY; NEVIRAPINE; VIRUS RNA; ZIDOVUDINE;

ANTIBODY RESPONSE; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LYMPHOCYTE COUNT; MALE; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; VIRUS CULTURE; VIRUS REPLICATION;

ADMINISTRATION, ORAL; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DISEASE TRANSMISSION, VERTICAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; NEVIRAPINE; PYRIDINES; RNA, VIRAL; VIRAL LOAD; ZIDOVUDINE;

EID: 0030990223     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199705083361902     Document Type: Article

References (24)

1. Stoneburner RL, Sato P, Burton A, Mertens T. The global HW pandemic. Acta Paediatr Suppl 1994;400:1-4.
2. The European Collaborative Study. Natural history of vertically acquired human immunodeficiency virus-1 infection. Pediatrics 1994;94:815-9.
3. Piatak M Jr, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749-54.
4. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
5. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
6. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo; virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6.
7. Luzuriaga K, Bryson Y, McSherry G, et al. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 1996;174:713-21.
8. AIDS Clinical Trials Group. Virology reference manual. Bethesda, Md.: National Institutes of Health, 1993.
9. Greenough TC, Brettler DB, Somasundaran M, Pamcali DL, Sullivan JL. HIV-1-specific cytotoxic T lymphocytes (CTL), viral load, and CD4 T cell loss: evidence supporting a predominantly protective role for CTL in vivo. J Infect Dis (in press).
10. Saag MS, Hoiodniy M, Kuritzkes DR, et al- HIV viral load markers in clinical practice. Nat Med 1996;2:625-9.
11. Christopherson C, Mulder J, Conway B, et al. Evaluation of HIV-1 proviral DNA in patients with undetectable RNA. Presented at the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22-26, 1997
12. Martin NL, Levy JA, Legg H, Weintrub PS, Cowan MJ, Wara DW. Detection of infection with human immunodeficiency virus (HIV) type 1 in infants by an anti-HIV immunoglobulin A assay using recombinant proteins. J Pediatr 1991;118:354-8.
13. Lubaki MN, Egan MA, Siliciano RF, Weinhold KJ, Bollinger RC. A novel method for detection and ex vivo expansion of HIV type 1-specific cytoiytic T lymphocytes. AIDS Res Hum Retroviruses 1994;10:1427-31.
14. Bryson YJ, Luzuriaga K, Sullivan JL, Wara DW. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992;327:1246-7
15. 1994 Revised classification system for human immunodeficiency virus infection in children Jess than 13 years of age. MMWR Morb Mortal Wkly Rep 1994;43(RR-12):1-10.
16. Luzuriaga K, Koup RA, Pikora CA, Brettler DB, Sullivan JL, Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children. J Pediatr 1991;119:230-6.
17. 197 conjugate vaccine in infants with human immunodeficiency virus infection. J Pediatr 1996;128;363-5.
18. 3. In: Abstracts of the XI International Conference on AIDS, Vancouver, B.C., July 7-12, 1996:22. abstract.
19. Bryson YJ, Pang S, Wei LS, Dickover R, Diagne A, Chen ISY. Clearance of HIV infection in a perinatally infected infant, N Engl J Med 1995;332:833-8.
20. Wyand MS, Manson KH, Lackner AA, Desrosiers RC. Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus. Nat Med 1997;3:32-6.
21. Coffin JM. HIV population dynamics in vivo: implications for genetic variation pathogencsis, and therapy. Science 1995;267:483-9.
22. Scarlatti G, Leitner T, Halapi E, et al. Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers. Proc NatI Acad Sci U S A 1993;90:1721-5.
23. Wolinsky SM, Wike CM, Korber BTM, et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992;255:1134-7
24. Luzuriaga K, Sullivan JL. DNA polymerase chain reaction for the diagnosis of vertical HIV infection. JAMA 1996;275:1360-1.